Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86
By Sept 8, 2023, 95 sequences were detected, of which their early sequences originated from multiple countries, had no epidemiological relevance, and were found in individuals without a history of travel, suggesting the presence of underlying international transmission (appendix 1 p 7). [...]an expe...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2023-11, Vol.23 (11), p.e457-e459 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e459 |
|---|---|
| container_issue | 11 |
| container_start_page | e457 |
| container_title | The Lancet infectious diseases |
| container_volume | 23 |
| creator | Yang, Sijie Yu, Yuanling Jian, Fanchong Song, Weiliang Yisimayi, Ayijiang Chen, Xiaosu Xu, Yanli Wang, Peng Wang, Jing Yu, Lingling Niu, Xiao Wang, Jing Xiao, Tianhe An, Ran Wang, Yao Gu, Qingqing Shao, Fei Jin, Ronghua Shen, Zhongyang Wang, Youchun Cao, Yunlong |
| description | By Sept 8, 2023, 95 sequences were detected, of which their early sequences originated from multiple countries, had no epidemiological relevance, and were found in individuals without a history of travel, suggesting the presence of underlying international transmission (appendix 1 p 7). [...]an experimental assessment of the antigenicity and infectivity of BA.2.86 is urgently needed. Saltation variants might have a compromised efficiency with regards to infecting host cells to gain a strong capability of evading neutralising antibodies elicited during the antibody–virus coevolution in long-term continuous host infection.8 Therefore, we next evaluated BA.2.86's cellular infectivity by testing the efficiency of its pseudovirus form to infect Vero cells and human ACE2-HEK293T cells (figure D; appendix 1 p 10). |
| doi_str_mv | 10.1016/S1473-3099(23)00573-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2868128285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S147330992300573X</els_id><sourcerecordid>2881747355</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-25ee70602026b163bcc25343bcfd9e4c2d9ac25f4a0d82340e95307b5c300b3b3</originalsourceid><addsrcrecordid>eNqFkEtLw0AQgBdRsFZ_ghDwUg-ps688ThKDLygIVqW3ZbPZ6JZ2U3fTQv-9m8aTF0_z4Jth5kPoEsMUA05u5pilNKaQ5xNCrwF4qBZHaBTaLGaMp8eHfEBO0Zn3SwCcYmAjVBa2M5_aGmW6fSRtHRnbaNWZXV-rL-mk6rQzXnamtVHbRPPidR6X7UdMortiSqZZco5OGrny-uI3jtH7w_1b-RTPXh6fy2IWK4bTLiZc6xQSIECSCie0UopwykJs6lwzRepchk7DJNQZoQx0zimkFVcUoKIVHaPJsHfj2u-t9p1YG6_0aiWtbrdekCzJMMlIxgN69Qddtltnw3WBynAabPCe4gOlXOu9043YOLOWbi8wiF6tOKgVvTdBqDioFYswdzvM6fDtzmgnvDLaKl0bF9yJujX_bPgBKOJ9aQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2881747355</pqid></control><display><type>article</type><title>Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Yang, Sijie ; Yu, Yuanling ; Jian, Fanchong ; Song, Weiliang ; Yisimayi, Ayijiang ; Chen, Xiaosu ; Xu, Yanli ; Wang, Peng ; Wang, Jing ; Yu, Lingling ; Niu, Xiao ; Wang, Jing ; Xiao, Tianhe ; An, Ran ; Wang, Yao ; Gu, Qingqing ; Shao, Fei ; Jin, Ronghua ; Shen, Zhongyang ; Wang, Youchun ; Cao, Yunlong</creator><creatorcontrib>Yang, Sijie ; Yu, Yuanling ; Jian, Fanchong ; Song, Weiliang ; Yisimayi, Ayijiang ; Chen, Xiaosu ; Xu, Yanli ; Wang, Peng ; Wang, Jing ; Yu, Lingling ; Niu, Xiao ; Wang, Jing ; Xiao, Tianhe ; An, Ran ; Wang, Yao ; Gu, Qingqing ; Shao, Fei ; Jin, Ronghua ; Shen, Zhongyang ; Wang, Youchun ; Cao, Yunlong</creatorcontrib><description>By Sept 8, 2023, 95 sequences were detected, of which their early sequences originated from multiple countries, had no epidemiological relevance, and were found in individuals without a history of travel, suggesting the presence of underlying international transmission (appendix 1 p 7). [...]an experimental assessment of the antigenicity and infectivity of BA.2.86 is urgently needed. Saltation variants might have a compromised efficiency with regards to infecting host cells to gain a strong capability of evading neutralising antibodies elicited during the antibody–virus coevolution in long-term continuous host infection.8 Therefore, we next evaluated BA.2.86's cellular infectivity by testing the efficiency of its pseudovirus form to infect Vero cells and human ACE2-HEK293T cells (figure D; appendix 1 p 10).</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(23)00573-X</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>ACE2 ; Angiotensin-converting enzyme 2 ; Antibodies ; Antigenicity ; Coevolution ; Efficiency ; Epidemiology ; Infections ; Infectious diseases ; Infectivity ; Mutation ; Plasma ; Saltation ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines ; Vero cells ; Viral diseases</subject><ispartof>The Lancet infectious diseases, 2023-11, Vol.23 (11), p.e457-e459</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-25ee70602026b163bcc25343bcfd9e4c2d9ac25f4a0d82340e95307b5c300b3b3</citedby><cites>FETCH-LOGICAL-c417t-25ee70602026b163bcc25343bcfd9e4c2d9ac25f4a0d82340e95307b5c300b3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2881747355?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids></links><search><creatorcontrib>Yang, Sijie</creatorcontrib><creatorcontrib>Yu, Yuanling</creatorcontrib><creatorcontrib>Jian, Fanchong</creatorcontrib><creatorcontrib>Song, Weiliang</creatorcontrib><creatorcontrib>Yisimayi, Ayijiang</creatorcontrib><creatorcontrib>Chen, Xiaosu</creatorcontrib><creatorcontrib>Xu, Yanli</creatorcontrib><creatorcontrib>Wang, Peng</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Yu, Lingling</creatorcontrib><creatorcontrib>Niu, Xiao</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Xiao, Tianhe</creatorcontrib><creatorcontrib>An, Ran</creatorcontrib><creatorcontrib>Wang, Yao</creatorcontrib><creatorcontrib>Gu, Qingqing</creatorcontrib><creatorcontrib>Shao, Fei</creatorcontrib><creatorcontrib>Jin, Ronghua</creatorcontrib><creatorcontrib>Shen, Zhongyang</creatorcontrib><creatorcontrib>Wang, Youchun</creatorcontrib><creatorcontrib>Cao, Yunlong</creatorcontrib><title>Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86</title><title>The Lancet infectious diseases</title><description>By Sept 8, 2023, 95 sequences were detected, of which their early sequences originated from multiple countries, had no epidemiological relevance, and were found in individuals without a history of travel, suggesting the presence of underlying international transmission (appendix 1 p 7). [...]an experimental assessment of the antigenicity and infectivity of BA.2.86 is urgently needed. Saltation variants might have a compromised efficiency with regards to infecting host cells to gain a strong capability of evading neutralising antibodies elicited during the antibody–virus coevolution in long-term continuous host infection.8 Therefore, we next evaluated BA.2.86's cellular infectivity by testing the efficiency of its pseudovirus form to infect Vero cells and human ACE2-HEK293T cells (figure D; appendix 1 p 10).</description><subject>ACE2</subject><subject>Angiotensin-converting enzyme 2</subject><subject>Antibodies</subject><subject>Antigenicity</subject><subject>Coevolution</subject><subject>Efficiency</subject><subject>Epidemiology</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Infectivity</subject><subject>Mutation</subject><subject>Plasma</subject><subject>Saltation</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><subject>Vero cells</subject><subject>Viral diseases</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkEtLw0AQgBdRsFZ_ghDwUg-ps688ThKDLygIVqW3ZbPZ6JZ2U3fTQv-9m8aTF0_z4Jth5kPoEsMUA05u5pilNKaQ5xNCrwF4qBZHaBTaLGaMp8eHfEBO0Zn3SwCcYmAjVBa2M5_aGmW6fSRtHRnbaNWZXV-rL-mk6rQzXnamtVHbRPPidR6X7UdMortiSqZZco5OGrny-uI3jtH7w_1b-RTPXh6fy2IWK4bTLiZc6xQSIECSCie0UopwykJs6lwzRepchk7DJNQZoQx0zimkFVcUoKIVHaPJsHfj2u-t9p1YG6_0aiWtbrdekCzJMMlIxgN69Qddtltnw3WBynAabPCe4gOlXOu9043YOLOWbi8wiF6tOKgVvTdBqDioFYswdzvM6fDtzmgnvDLaKl0bF9yJujX_bPgBKOJ9aQ</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Yang, Sijie</creator><creator>Yu, Yuanling</creator><creator>Jian, Fanchong</creator><creator>Song, Weiliang</creator><creator>Yisimayi, Ayijiang</creator><creator>Chen, Xiaosu</creator><creator>Xu, Yanli</creator><creator>Wang, Peng</creator><creator>Wang, Jing</creator><creator>Yu, Lingling</creator><creator>Niu, Xiao</creator><creator>Wang, Jing</creator><creator>Xiao, Tianhe</creator><creator>An, Ran</creator><creator>Wang, Yao</creator><creator>Gu, Qingqing</creator><creator>Shao, Fei</creator><creator>Jin, Ronghua</creator><creator>Shen, Zhongyang</creator><creator>Wang, Youchun</creator><creator>Cao, Yunlong</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>202311</creationdate><title>Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86</title><author>Yang, Sijie ; Yu, Yuanling ; Jian, Fanchong ; Song, Weiliang ; Yisimayi, Ayijiang ; Chen, Xiaosu ; Xu, Yanli ; Wang, Peng ; Wang, Jing ; Yu, Lingling ; Niu, Xiao ; Wang, Jing ; Xiao, Tianhe ; An, Ran ; Wang, Yao ; Gu, Qingqing ; Shao, Fei ; Jin, Ronghua ; Shen, Zhongyang ; Wang, Youchun ; Cao, Yunlong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-25ee70602026b163bcc25343bcfd9e4c2d9ac25f4a0d82340e95307b5c300b3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>ACE2</topic><topic>Angiotensin-converting enzyme 2</topic><topic>Antibodies</topic><topic>Antigenicity</topic><topic>Coevolution</topic><topic>Efficiency</topic><topic>Epidemiology</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Infectivity</topic><topic>Mutation</topic><topic>Plasma</topic><topic>Saltation</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><topic>Vero cells</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Sijie</creatorcontrib><creatorcontrib>Yu, Yuanling</creatorcontrib><creatorcontrib>Jian, Fanchong</creatorcontrib><creatorcontrib>Song, Weiliang</creatorcontrib><creatorcontrib>Yisimayi, Ayijiang</creatorcontrib><creatorcontrib>Chen, Xiaosu</creatorcontrib><creatorcontrib>Xu, Yanli</creatorcontrib><creatorcontrib>Wang, Peng</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Yu, Lingling</creatorcontrib><creatorcontrib>Niu, Xiao</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Xiao, Tianhe</creatorcontrib><creatorcontrib>An, Ran</creatorcontrib><creatorcontrib>Wang, Yao</creatorcontrib><creatorcontrib>Gu, Qingqing</creatorcontrib><creatorcontrib>Shao, Fei</creatorcontrib><creatorcontrib>Jin, Ronghua</creatorcontrib><creatorcontrib>Shen, Zhongyang</creatorcontrib><creatorcontrib>Wang, Youchun</creatorcontrib><creatorcontrib>Cao, Yunlong</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Sijie</au><au>Yu, Yuanling</au><au>Jian, Fanchong</au><au>Song, Weiliang</au><au>Yisimayi, Ayijiang</au><au>Chen, Xiaosu</au><au>Xu, Yanli</au><au>Wang, Peng</au><au>Wang, Jing</au><au>Yu, Lingling</au><au>Niu, Xiao</au><au>Wang, Jing</au><au>Xiao, Tianhe</au><au>An, Ran</au><au>Wang, Yao</au><au>Gu, Qingqing</au><au>Shao, Fei</au><au>Jin, Ronghua</au><au>Shen, Zhongyang</au><au>Wang, Youchun</au><au>Cao, Yunlong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86</atitle><jtitle>The Lancet infectious diseases</jtitle><date>2023-11</date><risdate>2023</risdate><volume>23</volume><issue>11</issue><spage>e457</spage><epage>e459</epage><pages>e457-e459</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>By Sept 8, 2023, 95 sequences were detected, of which their early sequences originated from multiple countries, had no epidemiological relevance, and were found in individuals without a history of travel, suggesting the presence of underlying international transmission (appendix 1 p 7). [...]an experimental assessment of the antigenicity and infectivity of BA.2.86 is urgently needed. Saltation variants might have a compromised efficiency with regards to infecting host cells to gain a strong capability of evading neutralising antibodies elicited during the antibody–virus coevolution in long-term continuous host infection.8 Therefore, we next evaluated BA.2.86's cellular infectivity by testing the efficiency of its pseudovirus form to infect Vero cells and human ACE2-HEK293T cells (figure D; appendix 1 p 10).</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S1473-3099(23)00573-X</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2023-11, Vol.23 (11), p.e457-e459 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2868128285 |
| source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | ACE2 Angiotensin-converting enzyme 2 Antibodies Antigenicity Coevolution Efficiency Epidemiology Infections Infectious diseases Infectivity Mutation Plasma Saltation Severe acute respiratory syndrome coronavirus 2 Vaccines Vero cells Viral diseases |
| title | Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T16%3A15%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antigenicity%20and%20infectivity%20characterisation%20of%20SARS-CoV-2%20BA.2.86&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Yang,%20Sijie&rft.date=2023-11&rft.volume=23&rft.issue=11&rft.spage=e457&rft.epage=e459&rft.pages=e457-e459&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(23)00573-X&rft_dat=%3Cproquest_cross%3E2881747355%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2881747355&rft_id=info:pmid/&rft_els_id=S147330992300573X&rfr_iscdi=true |